Conversion of Nightingale Health Plc’s Series A shares to Series B shares

Nightingale Health Plc | Stock Exchange Release | April 23, 2025 at 18:15:00 EEST

Nightingale Health Plc

The Board of Directors of Nightingale Health Plc (“Nightingale Health”) has in its meeting on 24 March 2025 approved request of shareholders to convert 151,670 Series A shares to Series B shares in accordance with Article 5 in the Articles of Association.

As a result of conversion of shares, the number of the Nightingale Health’s Series A shares is 19,374,768, Series B shares is 40,454,511, and EMP shares is 1,098,800. The conversion does not affect the total amount of shares which is 60,928,079. After the conversion, the number of votes of Nightingale Health’s shares is 234,202,191.

The conversions of shares were registered in the Trade Register on 23 April 2025. The converted shares will be listed on the Official List of Nasdaq Helsinki together with the old shares as of 24 April 2025.

About Nightingale Health
Nightingale Health has developed the world's most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The Company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/